MTOR and urinary bladder cancer: Jolkinolide B (JB) inhibited both AKT signaling and cytoprotective autophagy, potentiating the anti-proliferative efficacy of the mTOR inhibitor in both PTEN-deficient and cisplatin-resistant bladder cancer cells [151].